West Pharmaceutical Services Inc Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 29, 2026 results vs estimates
West Pharmaceutical Services Inc Forecast
West Pharmaceutical Services Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 20.1% a year, a typical one-standard-deviation range is 386.99–409.59 over a week, 375.14–421.44 over a month and 318.09–478.49 over a year. (Signals as of 1 Nov 2026.)
West Pharmaceutical Services Inc Price Chart
West Pharmaceutical Services Inc Factors
YoY +10.1%
YoY +27.1%
YoY +47.1%
YoY +15.6%
YoY +28.5%
YoY −16.4%
YoY −9.2%
YoY −27.7%
YoY +43.1%
YoY −51.9%
YoY −61.6%
YoY −1.8%
YoY −3.8%
YoY −86.7%
YoY +5.4%
YoY 0.0%
YoY +33.2%
West Pharmaceutical Services Inc fundamentals: income statement, balance sheet & cash flow
West Pharmaceutical Services Inc reported revenue of $3.07bn and net income of $493.7m in FY2025, the year ended 31 December 2025 — revenue up 6.3% and net income up 0.2% on the prior year. Free cash flow was $468.9m. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 3,073.7 | 2,892.7 | 2,951.1 | 2,885.5 | 2,830.7 |
| Cost of revenue | 1,970.4 | 1,890.5 | 1,818.4 | 1,746.6 | 1,657.3 |
| Gross profit | 1,103.3 | 1,002.2 | 1,132.7 | 1,138.9 | 1,173.4 |
| Research & development | 74.3 | 69.1 | 68.4 | 58.5 | 52.8 |
| Selling, general & admin. | — | 338.5 | 353.4 | — | 362.8 |
| Operating income | 617.4 | 594.6 | 710.9 | 763.5 | 758.7 |
| EBITDA | 770.6 | 743.8 | 844.1 | 808.1 | 879.7 |
| Interest expense | 0.6 | 2.9 | 8.8 | 7.6 | 8.5 |
| Pre-tax income | 615.3 | 600.2 | 715.7 | 700.6 | 769.0 |
| Income tax | 121.6 | 107.5 | 122.3 | 114.7 | 107.2 |
| Net income | 493.7 | 492.7 | 593.4 | 585.9 | 661.8 |
Download West Pharmaceutical Services Inc fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.WST.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on West Pharmaceutical Services Inc
Explore MacroFinance macro & markets research and analysis.
West Pharmaceutical Services Inc Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to West Pharmaceutical Services Inc; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow West Pharmaceutical Services Inc’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About West Pharmaceutical Services Inc (United States)
West Pharmaceutical Services Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
Frequently asked questions
What is West Pharmaceutical Services Inc?
What is the latest West Pharmaceutical Services Inc price?
Is West Pharmaceutical Services Inc in an uptrend?
How volatile is West Pharmaceutical Services Inc?
What factors affect West Pharmaceutical Services Inc?
Which trading strategies trade West Pharmaceutical Services Inc?
How are West Pharmaceutical Services Inc returns analysed?
Where can I download free West Pharmaceutical Services Inc historical data?
Free West Pharmaceutical Services Inc historical data (last 10 years)
Browse or instantly download the last 10 years of West Pharmaceutical Services Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.WST.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 390.3 |
| 2026-11-19 | 396.69 |
| 2026-11-18 | 404.02 |
| 2026-11-17 | 414.12 |
| 2026-11-16 | 417.8 |
| 2026-11-13 | 416.42 |
| 2026-11-12 | 411.3 |
| 2026-11-11 | 412.86 |
| 2026-11-10 | 412.55 |
| 2026-11-09 | 412.83 |
About this stock
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.